TIDMNCYT

RNS Number : 2193Y

Novacyt S.A.

02 January 2024

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Appointment of CFO

Paris, France, and Eastleigh and Manchester, UK - 2 January - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Steve Gibson as Chief Financial Officer with immediate effect. Mr Gibson will become a Board Director of the Company, subject to shareholder approval, at the Company's Annual General Meeting.

Steve joined Novacyt in 2017 and has served as Group Finance Director since 2020. Prior to joining Novacyt, Steve spent over 10 years in various finance departments at Hewlett-Packard and then Hewlett Packard Enterprise in positions of increasing seniority. Steve is a Chartered Management Accountant (CIMA) and has more than 18 years of international commercial experience.

Commenting, James Wakefield, Non-Executive Chairman, said: "We are delighted to welcome Steve as our CFO. He has impressed us with his financial and operational expertise and was instrumental in the acquisition of Yourgene Health plc as well as delivering the strategic changes to the Company over the last two years. The Board looks forward to working with him as we continue to execute our growth strategy."

Additional Disclosures Required under the AIM Rules for Companies

Steven Michael Gibson (aged 41) has held the following directorship or partnerships in the past five years:

 
 Current directorships/partnerships    Previous directorships/partnerships 
                                        (last five years) 
 Lab21 Healthcare Limited 
  Biotec Laboratories Limited 
  Primer Design Limited 
  Microgen Bioproducts Limited 
  Novacyt UK Holdings Limited 
  IT-IS International Limited 
  Delta Diagnostics (UK) Limited 
  Yourgene Health Limited 
  Yourgene Health UK Limited 
  Yourgene Genomic Services Limited 
  Elucigene Limited 
  Yourgene Health Canada Investments 
  Yourgene Health Canada Holdings 
  Yourgene Health Inc 
------------------------------------  ------------------------------------

Mr Gibson and persons closely associated (as defined under MAR) with Mr Gibson currently hold 9,116 ordinary shares of EUR1/15 each in the Company.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

Contacts

 
 Novacyt SA                                                                     https://novacyt.com/investors 
 James Wakefield, Non-Executive                                                               Via Walbrook PR 
  Chairman 
  James McCarthy, Acting Chief Executive 
  Officer 
 
 SP Angel Corporate Finance LLP (Nominated 
  Adviser and Broker)                                                                     +44 (0)20 3470 0470 
 Matthew Johnson / Charlie Bouverat (Corporate 
  Finance) 
  Vadim Alexandre / Rob Rees (Corporate Broking) 
 
 Deutsche Numis (Joint Broker)                                                            +44 (0)20 7260 1000 
 Freddie Barnfield / Duncan Monteith / Michael 
  Palser 
 
 Allegra Finance (French Listing                                                          +33 (1) 42 22 10 10 
  Sponsor)                                         r.durgetto@allegrafinance.com / y.petit@allegrafinance.com 
  Rémi Durgetto / Yannick 
  Petit 
 
 Walbrook PR (Financial PR & IR)                                +44 (0)20 7933 8780 or novacyt@walbrookpr.com 
  Stephanie Cuthbert / Paul McManus                                          +44 (0)7796 794 663/ +44 (0)7980 
  /                                                                                                   541 893 
  Phillip Marriage / Alice Woodings                                        + 44 (0)7867 984 082 / +44 (0)7407 
                                                                                                      804 654

About Novacyt Group ( www.novacyt.com )

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei (divestment pending), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOATLBMTMTJTBTJ

(END) Dow Jones Newswires

January 02, 2024 02:00 ET (07:00 GMT)

Grafico Azioni Novacyt (LSE:NCYT)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Novacyt
Grafico Azioni Novacyt (LSE:NCYT)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Novacyt